All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

BMYBristol-Myers Squibb
10Calm
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Signing up patientsPhase 1/2474 patientsMain results: Nov 28, 2029
BMYBristol-Myers Squibb
10Calm
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Signing up patientsPhase 2160 patientsMain results: Sep 15, 2028
BMYBristol-Myers Squibb
10Calm
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Signing up patientsPhase 3750 patientsMain results: Oct 14, 2031
NVSNovartis Pharmaceuticals
5Calm
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Running, no new patientsPhase 1/225 patientsMain results: Jun 11, 2029
VSTMVerastem, Inc.
12Calm
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Signing up patientsPhase 1/2616 patientsMain results: Dec 2028
MRKMerck Sharp & Dohme LLC
5Calm
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Running, no new patientsPhase 31,397 patientsMain results: Jul 31, 2028
BMYBristol-Myers Squibb
10Calm
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Signing up patientsPhase 2/3590 patientsMain results: Aug 12, 2031
ANTXAN2 Therapeutics, Inc
0Calm
Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera
Not started yetPhase 275 patientsMain results: Apr 2029
BMYBristol-Myers Squibb
10Calm
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Signing up patientsPhase 1/2198 patientsMain results: Oct 15, 2029
AZNAstraZeneca
0Calm
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Running, no new patientsPhase 3863 patientsMain results: Nov 16, 2028
ONCBeOne Medicines
2Calm
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Signing up patientsPhase 3630 patientsMain results: Sep 30, 2029
AMGNAmgen
12Calm
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
FinishedPhase 3547 patientsMain results: Jun 20, 2025
AZNAstraZeneca
0Calm
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Signing up patientsPhase 1/285 patientsMain results: Feb 15, 2029
GSKGlaxoSmithKline
0Calm
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Signing up patientsPhase 3800 patientsMain results: Aug 30, 2032
AZNAstraZeneca
0Calm
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
Signing up patientsPhase 280 patientsMain results: May 1, 2029
AZNAcerta Pharma BV
0Calm
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Running, no new patientsPhase 3310 patientsMain results: Sep 3, 2021
TNGXTango Therapeutics, Inc.
0Calm
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Signing up patientsPhase 1/2183 patientsMain results: Jun 2027
BMYBristol-Myers Squibb
10Calm
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Signing up patientsPhase 1/2460 patientsMain results: Oct 28, 2027
RVMDRevolution Medicines, Inc.
0Calm
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Signing up patientsPhase 3500 patientsMain results: May 10, 2029
AMGNAmgen
2Calm
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
FinishedPhase 3165 patientsMain results: Jan 25, 2024
TAKTakeda
5Calm
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
FinishedPhase 3354 patientsMain results: Sep 22, 2026
URGNUroGen Pharma Ltd.
5Calm
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
FinishedPhase 399 patientsMain results: Sep 11, 2025
TAKTakeda
5Calm
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
FinishedPhase 1/2248 patientsMain results: Mar 30, 2026
AZNAstraZeneca
0Calm
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Running, no new patientsPhase 282 patientsMain results: Jun 30, 2027
REGNRegeneron Pharmaceuticals
5Calm
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Signing up patientsPhase 2120 patientsMain results: Jun 4, 2028